{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:43:22Z","timestamp":1792579402692,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371266"],"award-info":[{"award-number":["82371266"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171252"],"award-info":[{"award-number":["82171252"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171421"],"award-info":[{"award-number":["82171421"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371432"],"award-info":[{"award-number":["82371432"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92249302"],"award-info":[{"award-number":["92249302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010120","name":"Huashan Hospital","doi-asserted-by":"publisher","award":["2023-YN008"],"award-info":[{"award-number":["2023-YN008"]}],"id":[{"id":"10.13039\/501100010120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","award":["Pro20211231084249000238"],"award-info":[{"award-number":["Pro20211231084249000238"]}],"id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22JC1410402"],"award-info":[{"award-number":["22JC1410402"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00702-025-03031-w","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:41:00Z","timestamp":1759761660000},"page":"2867-2875","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cross-sectional and longitudinal validation of short and long versions of the progressive supranuclear palsy quality of life scale"],"prefix":"10.1007","volume":"133","author":[{"given":"Qi","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KunWang","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Niu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"3031_CR1","unstructured":"Angelo C, Brian R (2024) boot: Bootstrap R (S-Plus) Functions. R package version 1.3\u201331. https:\/\/CRAN.R-project.org\/package=boot"},{"key":"3031_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.parkreldis.2016.04.014","volume":"28","author":"J Bang","year":"2016","unstructured":"Bang J, Lobach IV, Lang AE et al (2016) Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord 28:41\u201348. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.014","journal-title":"Parkinsonism Relat Disord"},{"key":"3031_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1474-4422(17)30157-6","volume":"16","author":"AL Boxer","year":"2017","unstructured":"Boxer AL, Yu J-T, Golbe LI et al (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16:552\u2013563. https:\/\/doi.org\/10.1016\/S1474-4422(17)30157-6","journal-title":"Lancet Neurol"},{"key":"3031_CR5","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/mds.30052","volume":"39","author":"A Cappiello","year":"2024","unstructured":"Cappiello A, Barone P, Picillo M et al (2024) A short progressive supranuclear palsy quality of life scale: data from the PSP-NET. Mov Disord 39:2305\u20132307. https:\/\/doi.org\/10.1002\/mds.30052","journal-title":"Mov Disord"},{"key":"3031_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.14802\/jmd.19066","volume":"13","author":"SP Chaithra","year":"2020","unstructured":"Chaithra SP, Prasad S, Holla VV et al (2020) The non-motor symptom profile of progressive supranuclear palsy. J Mov Disord 13:118\u2013126. https:\/\/doi.org\/10.14802\/jmd.19066","journal-title":"J Mov Disord"},{"key":"3031_CR4","unstructured":"Champely S (2020) PWR: basic functions for power analysis. R package version 1.3\u20130. https:\/\/CRAN.R-project.org\/package=pwr"},{"key":"3031_CR7","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for parkinson\u2019s disease: results from an international pilot study. Mov Disord 22:1901\u20131911. https:\/\/doi.org\/10.1002\/mds.21596","journal-title":"Mov Disord"},{"key":"3031_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/brain\/awf082","volume":"125","author":"NJ Cordato","year":"2002","unstructured":"Cordato NJ, Pantelis C, Halliday GM et al (2002) Frontal atrophy correlates with behavioural changes in progressive supranuclear palsy. Brain 125:789\u2013800. https:\/\/doi.org\/10.1093\/brain\/awf082","journal-title":"Brain"},{"key":"3031_CR9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00702-023-02676-9","volume":"130","author":"S Cuoco","year":"2023","unstructured":"Cuoco S, Ponticorvo S, Abate F et al (2023) Frequency and imaging correlates of neuropsychiatric symptoms in progressive supranuclear palsy. J Neural Transm Vienna Austria 1996 130:1259\u20131267. https:\/\/doi.org\/10.1007\/s00702-023-02676-9","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"3031_CR10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","volume":"27","author":"T Dam","year":"2021","unstructured":"Dam T, Boxer AL, Golbe LI et al (2021) Safety and efficacy of anti-tau monoclonal antibody Gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med 27:1451\u20131457. https:\/\/doi.org\/10.1038\/s41591-021-01455-x","journal-title":"Nat Med"},{"key":"3031_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1177\/0891988721993545","volume":"35","author":"J Flavell","year":"2022","unstructured":"Flavell J, Nestor PJ (2022) A systematic review of apathy and depression in progressive supranuclear palsy. J Geriatr Psychiatry Neurol 35:280\u2013292. https:\/\/doi.org\/10.1177\/0891988721993545","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"3031_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189\u2013198. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6","journal-title":"J Psychiatr Res"},{"key":"3031_CR13","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/brain\/awm032","volume":"130","author":"LI Golbe","year":"2007","unstructured":"Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130:1552\u20131565. https:\/\/doi.org\/10.1093\/brain\/awm032","journal-title":"Brain"},{"key":"3031_CR15","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A et al (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 20:1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual Life Res"},{"key":"3031_CR14","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/mds.21237","volume":"22","author":"B Herting","year":"2007","unstructured":"Herting B, Beuthien-Baumann B, P\u00f6ttrich K et al (2007) Prefrontal cortex dysfunction and depression in atypical parkinsonian syndromes. Mov Disord 22:490\u2013497. https:\/\/doi.org\/10.1002\/mds.21237","journal-title":"Mov Disord"},{"key":"3031_CR16","doi-asserted-by":"publisher","first-page":"e46327","DOI":"10.1371\/journal.pone.0046327","volume":"7","author":"IJ Higginson","year":"2012","unstructured":"Higginson IJ, Gao W, Saleem TZ et al (2012) Symptoms and quality of life in late stage Parkinson syndromes: a longitudinal community study of predictive factors. PLoS One 7:e46327. https:\/\/doi.org\/10.1371\/journal.pone.0046327","journal-title":"PLoS One"},{"key":"3031_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU H\u00f6glinger","year":"2017","unstructured":"H\u00f6glinger GU, Respondek G, Stamelou M et al (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32:853\u2013864. https:\/\/doi.org\/10.1002\/mds.26987","journal-title":"Mov Disord"},{"key":"3031_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","volume":"20","author":"GU H\u00f6glinger","year":"2021","unstructured":"H\u00f6glinger GU, Litvan I, Mendonca N et al (2021) Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol 20:182\u2013192. https:\/\/doi.org\/10.1016\/S1474-4422(20)30489-0","journal-title":"Lancet Neurol"},{"key":"3031_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamaneurol.2019.4347","volume":"77","author":"E Jabbari","year":"2020","unstructured":"Jabbari E, Holland N, Chelban V et al (2020) Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurol 77:377\u2013387. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4347","journal-title":"JAMA Neurol"},{"key":"3031_CR21","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00415-014-7384-x","volume":"261","author":"M Jecmenica-Lukic","year":"2014","unstructured":"Jecmenica-Lukic M, Petrovic IN, Pekmezovic T, Kostic VS (2014) Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study. J Neurol 261:1575\u20131583. https:\/\/doi.org\/10.1007\/s00415-014-7384-x","journal-title":"J Neurol"},{"key":"3031_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","volume":"26","author":"C Jenkinson","year":"1997","unstructured":"Jenkinson C, Fitzpatrick R, Peto V et al (1997) The parkinson\u2019s disease questionnaire (PDQ-39): development and validation of a parkinson\u2019s disease summary index score. Age Ageing 26:353\u2013357. https:\/\/doi.org\/10.1093\/ageing\/26.5.353","journal-title":"Age Ageing"},{"key":"3031_CR23","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/mds.29936","volume":"39","author":"I Jensen","year":"2024","unstructured":"Jensen I, Stiel S, Bebermeier S et al (2024) A short progressive supranuclear palsy quality of life scale. Mov Disord 39:1602\u20131609. https:\/\/doi.org\/10.1002\/mds.29936","journal-title":"Mov Disord"},{"key":"3031_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14:540\u2013545. https:\/\/doi.org\/10.1093\/sleep\/14.6.540","journal-title":"Sleep"},{"key":"3031_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1017\/s0317167100021053","volume":"24","author":"A Kertesz","year":"1997","unstructured":"Kertesz A, Davidson W, Fox H (1997) Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia. Can J Neurol Sci 24:29\u201336. https:\/\/doi.org\/10.1017\/s0317167100021053","journal-title":"Can J Neurol Sci"},{"key":"3031_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","volume":"140","author":"GG Kovacs","year":"2020","unstructured":"Kovacs GG, Lukic MJ, Irwin DJ et al (2020) Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol (Berl) 140:99\u2013119. https:\/\/doi.org\/10.1007\/s00401-020-02158-2","journal-title":"Acta Neuropathol (Berl)"},{"key":"3031_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jns.2013.01.034","volume":"327","author":"C-N Lee","year":"2013","unstructured":"Lee C-N, Kim M, Lee HM et al (2013) The interrelationship between non-motor symptoms in atypical parkinsonism. J Neurol Sci 327:15\u201321. https:\/\/doi.org\/10.1016\/j.jns.2013.01.034","journal-title":"J Neurol Sci"},{"key":"3031_CR26","volume-title":"Nonparametrics: statistical methods based on ranks","author":"EL Lehmann","year":"2006","unstructured":"Lehmann EL, D\u2019Abrera HJ (2006) Nonparametrics: statistical methods based on ranks. Springer, New York"},{"key":"3031_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3233\/JPD-223553","volume":"13","author":"X-Y Li","year":"2023","unstructured":"Li X-Y, Chen M-J, Liang X-N et al (2023) PDQ-8: A simplified and effective tool measuring life quality in progressive supranuclear palsy. J Parkinsons Dis 13:83\u201391","journal-title":"J Parkinsons Dis"},{"key":"3031_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/mdc3.14315","volume":"12","author":"X-Y Li","year":"2024","unstructured":"Li X-Y, Yang Y-J, Jiao F-Y et al (2024) Rapid cognitive deterioration in progressive supranuclear palsy: a 1-year follow-up study. Mov Disord Clin Pract 12:475\u2013483. https:\/\/doi.org\/10.1002\/mdc3.14315","journal-title":"Mov Disord Clin Pract"},{"key":"3031_CR30","doi-asserted-by":"publisher","first-page":"1476488","DOI":"10.3389\/fneur.2024.1476488","volume":"15","author":"M Markiewicz","year":"2024","unstructured":"Markiewicz M, Madetko-Alster N, Alster P (2024) Quality of life in patients with progressive supranuclear palsy: a review of literature and implications for practice. Front Neurol 15:1476488. https:\/\/doi.org\/10.3389\/fneur.2024.1476488","journal-title":"Front Neurol"},{"key":"3031_CR31","doi-asserted-by":"publisher","first-page":"e70248","DOI":"10.1111\/ene.70248","volume":"32","author":"A Morales-Rivero","year":"2025","unstructured":"Morales-Rivero A, Garcia-Cordero I, Khoja A et al (2025) The impact of neuropsychiatric symptoms in perceived quality of life in patients with progressive supranuclear palsy. Eur J Neurol 32:e70248. https:\/\/doi.org\/10.1111\/ene.70248","journal-title":"Eur J Neurol"},{"key":"3031_CR32","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jns.2017.07.033","volume":"380","author":"R Ou","year":"2017","unstructured":"Ou R, Liu H, Hou Y et al (2017) Executive dysfunction, behavioral changes and quality of life in Chinese patients with progressive supranuclear palsy. J Neurol Sci 380:182\u2013186. https:\/\/doi.org\/10.1016\/j.jns.2017.07.033","journal-title":"J Neurol Sci"},{"key":"3031_CR33","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jad.2020.07.127","volume":"276","author":"R Ou","year":"2020","unstructured":"Ou R, Wei Q, Hou Y et al (2020) Suicidal and death ideation in patients with progressive supranuclear palsy and corticobasal syndrome. J Affect Disord 276:1061\u20131068. https:\/\/doi.org\/10.1016\/j.jad.2020.07.127","journal-title":"J Affect Disord"},{"key":"3031_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.parkreldis.2020.03.003","volume":"74","author":"C Painous","year":"2020","unstructured":"Painous C, Mart\u00ed MJ, Simonet C et al (2020) Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: the step-back PSP study. Parkinsonism Relat Disord 74:67\u201373. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.03.003","journal-title":"Parkinsonism Relat Disord"},{"key":"3031_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000514519","volume":"20","author":"A Pantelyat","year":"2021","unstructured":"Pantelyat A, Higginbotham L, Rosenthal L et al (2021) Association of progressive supranuclear palsy rating scale with progressive supranuclear palsy quality of life scale. Neurodegener Dis 20:139\u2013146. https:\/\/doi.org\/10.1159\/000514519","journal-title":"Neurodegener Dis"},{"key":"3031_CR37","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1007\/s00415-015-7815-3","volume":"262","author":"T Pekmezovi\u0107","year":"2015","unstructured":"Pekmezovi\u0107 T, Je\u010dmenica-Luki\u0107 M, Petrovi\u0107 I et al (2015) Quality of life in patients with progressive supranuclear palsy: one-year follow-up. J Neurol 262:2042\u20132048. https:\/\/doi.org\/10.1007\/s00415-015-7815-3","journal-title":"J Neurol"},{"key":"3031_CR34","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF02260863","volume":"4","author":"V Peto","year":"1995","unstructured":"Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with parkinson\u2019s disease. Qual Life Res 4:241\u2013248. https:\/\/doi.org\/10.1007\/BF02260863","journal-title":"Qual Life Res"},{"key":"3031_CR38","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1007\/s10072-019-04010-2","volume":"40","author":"M Picillo","year":"2019","unstructured":"Picillo M, Cuoco S, Amboni M et al (2019) Validation of the Italian version of the PSP quality of life questionnaire. Neurol Sci 40:2587\u20132594. https:\/\/doi.org\/10.1007\/s10072-019-04010-2","journal-title":"Neurol Sci"},{"key":"3031_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/mdc3.13958","volume":"11","author":"I Ruiz-Barrio","year":"2024","unstructured":"Ruiz-Barrio I, Horta-Barba A, Aracil-Bola\u00f1os I et al (2024) Predicting disability in progressive supranuclear palsy using bedside Frontal-Lobe signs. Mov Disord Clin Pract 11:248\u2013256. https:\/\/doi.org\/10.1002\/mdc3.13958","journal-title":"Mov Disord Clin Pract"},{"key":"3031_CR40","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1007\/s00415-018-9038-x","volume":"265","author":"G Santangelo","year":"2018","unstructured":"Santangelo G, Cuoco S, Pellecchia MT et al (2018) Comparative cognitive and neuropsychiatric profiles between parkinson\u2019s disease, multiple system atrophy and progressive supranuclear palsy. J Neurol 265:2602\u20132613. https:\/\/doi.org\/10.1007\/s00415-018-9038-x","journal-title":"J Neurol"},{"key":"3031_CR41","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.10583","volume":"18","author":"A Schrag","year":"2003","unstructured":"Schrag A, Selai C, Davis J et al (2003) Health-related quality of life in patients with progressive supranuclear palsy. Mov Disord 18:1464\u20131469. https:\/\/doi.org\/10.1002\/mds.10583","journal-title":"Mov Disord"},{"key":"3031_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1212\/01.wnl.0000223826.84080.97","volume":"67","author":"A Schrag","year":"2006","unstructured":"Schrag A, Selai C, Quinn N et al (2006) Measuring quality of life in PSP: the PSP-QoL. Neurology 67:39\u201344. https:\/\/doi.org\/10.1212\/01.wnl.0000223826.84080.97","journal-title":"Neurology"},{"key":"3031_CR43","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/mds.22794","volume":"25","author":"A Schrag","year":"2010","unstructured":"Schrag A, Sheikh S, Quinn NP et al (2010) A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 25:1077\u20131081. https:\/\/doi.org\/10.1002\/mds.22794","journal-title":"Mov Disord"},{"key":"3031_CR44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.parkreldis.2019.07.010","volume":"66","author":"A Shoeibi","year":"2019","unstructured":"Shoeibi A, Litvan I, Tolosa E et al (2019) Progression of two progressive supranuclear palsy phenotypes with comparable initial disability. Parkinsonism Relat Disord 66:87\u201393. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.07.010","journal-title":"Parkinsonism Relat Disord"},{"key":"3031_CR47","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/mds.26580","volume":"31","author":"M Stamelou","year":"2016","unstructured":"Stamelou M, Sch\u00f6pe J, Wagenpfeil S et al (2016) Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Mov Disord 31:742\u2013747. https:\/\/doi.org\/10.1002\/mds.26580","journal-title":"Mov Disord"},{"key":"3031_CR46","doi-asserted-by":"publisher","first-page":"fcab206","DOI":"10.1093\/braincomms\/fcab206","volume":"3","author":"D Street","year":"2021","unstructured":"Street D, Malpetti M, Rittman T et al (2021) Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants. Brain Commun 3:fcab206. https:\/\/doi.org\/10.1093\/braincomms\/fcab206","journal-title":"Brain Commun"},{"key":"3031_CR45","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/brain\/awad105","volume":"146","author":"D Street","year":"2023","unstructured":"Street D, Jabbari E, Costantini A et al (2023) Progression of atypical parkinsonian syndromes: PROSPECT-M-UK study implications for clinical trials. Brain 146:3232\u20133242. https:\/\/doi.org\/10.1093\/brain\/awad105","journal-title":"Brain"},{"key":"3031_CR48","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mds.25824","volume":"29","author":"E Tolosa","year":"2014","unstructured":"Tolosa E, Litvan I, H\u00f6glinger GU et al (2014) A phase 2 trial of the GSK-3 inhibitor Tideglusib in progressive supranuclear palsy. Mov Disord 29:470\u2013478. https:\/\/doi.org\/10.1002\/mds.25824","journal-title":"Mov Disord"},{"key":"3031_CR50","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","volume":"8","author":"DR Williams","year":"2009","unstructured":"Williams DR, Lees AJ (2009) Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 8:270\u2013279. https:\/\/doi.org\/10.1016\/S1474-4422(09)70042-0","journal-title":"Lancet Neurol"},{"key":"3031_CR49","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/brain\/awm104","volume":"130","author":"DR Williams","year":"2007","unstructured":"Williams DR, Holton JL, Strand C et al (2007) Pathological Tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from richardson\u2019s syndrome. Brain 130:1566\u20131576. https:\/\/doi.org\/10.1093\/brain\/awm104","journal-title":"Brain"},{"key":"3031_CR51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","volume":"17","author":"JA Yesavage","year":"1982","unstructured":"Yesavage JA, Brink TL, Rose TL et al (1982) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37\u201349. https:\/\/doi.org\/10.1016\/0022-3956(82)90033-4","journal-title":"J Psychiatr Res"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03031-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03031-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03031-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:18:40Z","timestamp":1792577920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03031-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3031"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03031-w","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Supplementary Materialhas been updated","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved (KY-2019-284, KY-2020-1160) and supervised by the Ethics Committee of Huashan Hospital. All subjects provided written informed consent according to the Declaration of Helsink before entering the study.","order":2,"name":"Ethics","label":"Consent and ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}